Zisman Amnon
Urology Department, Assaf-Harofeh Medical Center, Zerifin.
Harefuah. 2002 Aug;141(8):713-7, 761.
In the last decade the treatment of renal cell carcinoma (RCC) have changed dramatically. Currently, laparoscopic radical nephrectomy, partial nephrectomy in the presence of normal contralateral kidney as well as ablative surgery for small renal masses, are vivid options for the treatment of localized RCC. For metastatic RCC, cytoreductive nephrectomy is the standard of care prior to immunotherapy or combined treatment with tumor vaccines. On the horizon are: laparoscopic partial nephrectomy for localized disease and allogenic dendritic cell--autologous tumor cell hybrid vaccines as a non-toxic tumor vaccine. More experimental therapies involving targeting RCC cells using specific markers such as G250 are under investigation. In addition, changes in the 1997 TNM classification of RCC are anticipated. Retiring--routine adrenalectomy during radical nephrectomy and immunotherapy using tumor infiltrating lymphocytes (TIL).
在过去十年中,肾细胞癌(RCC)的治疗发生了巨大变化。目前,腹腔镜根治性肾切除术、对侧肾脏正常情况下的部分肾切除术以及小肾肿块的消融手术,都是治疗局限性RCC的可行选择。对于转移性RCC,减瘤性肾切除术是免疫治疗或与肿瘤疫苗联合治疗之前的标准治疗方法。未来可期的有:针对局限性疾病的腹腔镜部分肾切除术以及作为无毒肿瘤疫苗的同种异体树突状细胞——自体肿瘤细胞杂交疫苗。更多涉及使用G250等特定标志物靶向RCC细胞的实验性疗法正在研究中。此外,预计1997年RCC的TNM分类会有变化。根治性肾切除术中不再常规进行肾上腺切除术,以及使用肿瘤浸润淋巴细胞(TIL)进行免疫治疗。